Daily Mail Reporter
A new hybrid of ‘superdrug’ aspirin could shrink tumours and may tackle 11 different forms of cancer, according to new research.
The ‘designer’ aspirin is believed to be much safer than the version currently on chemist shelves, which can cause bleeding, ulcers and kidney failure in high doses.
Scientists discovered the aspirin compound can curb the growth of 11 different types of human cancer cells – including colon, pancreatic, prostate, breast and leukemia – without harming normal cells. However, so far it has only been tested on animals.
Mice carrying human colon cancer tumours were given the new aspirin, known as NOSH aspirin, It caused the cancer cells to shrink by 85 per cent and self-destruct – without any signs of toxicity in the mice.
Lead author Professor Khosrow Kashfi from The City College of New York, said: ‘If what we have seen in animals can be translated to humans, it could be used in conjunction with other drugs to shrink tumors before chemotherapy or surgery.’